Outlook and New Beginnings

With ASCO approaching and some major market moving events, I just wanted to provide some perspective with earnings season almost over. – I get the impression that ASCO will be.

Dissecting the ASCO 2014 abstract titles

Today, the American Society for Clinical Oncology(ASCO) posted a link to the ASCO 2014 meeting planner[LINK]. The planner also includes all of the abstract titles at the meeting. ASCO 2014.

Corcept – Fourth time a charm?

Corcept Therapeutics (CORT) is currently awaiting topline Phase III data for Korlym(mifepristone) in psychotic depression in the second quarter. Currently, Corcept projects Korlym will do net revenue between $24-$28 million.

Upcoming events for Merck

Members of Chimera Research Group have successfully been trading Merck for the past few months, especially Joe Gantos(@GantosJ). Merck has been one of the strongest big pharmas over the past.

Upcoming events for Pfizer

Pfizer (PFE) isn’t traditionally on my watchlist as a name to follow, however, this may be an exception. Palbocicib is likely the most exciting pipeline product in development at Pfizer.

A look at Auspex Pharma

Lately, it seems like there is a new biotech IPO being filed every other day. Today, we want to take a look at a recent IPO, Auspex Pharmaceuticals (ASPX). Auspex.

Update on Protalix

On Wednesday, Protalix (PLX) will present data from their phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. The presentation will be.

Prospects for Prana's PBT2

On the wildly speculative front, Prana Biotechnology (PRAN) is a developer of metal protein attenuating compounds(MPAC) for neurodegenerative disorders. Shares are up over 350% in the past year as the.

Upcoming Phase 3 trials

With a fresh start to 2014 and the biotech market still very strong, we wanted to examine some upcoming Phase 3 results that will be in focus in the first.

A look at Innate Pharma

Immuno-oncology was one of the hottest themes of 2013 and its been almost entirely a big pharma story. We saw Bristol-Myers Squibb, Merck and Roche reveal more data and future.

TSRO – A look at Tesaro

Following additional information released at ASCO 2013 and their recent quarterly updated, we wanted to take a moment to talk about Tesaro (TSRO). Since their IPO, Tesaro’s stock is up.

Horizon Pharma continues cash burn and dilution

We last wrote on Horizon Pharma (NASDAQ: HZNP) following their FDA approval of RAYOS, but seems not much has changed. However, the stock has risen roughly 60% year to date.

ASH 2013 Preview on ALL/CML/MDS/AML

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. The first series in our preview covered what to expect in.

ASH 2013 Preview on Lymphoid Malignancies

This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking.

ASH 2013 Preview on rare blood disorders

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. Orphan diseases has been a key element in the bull market.

ASH 2013 Preview on Multiple Myeloma

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs.

CLDX – A look at CDX-1127

Celldex Therapeutics (CLDX) has one of the most anticipated data releases amongst small biotech companies this fall. They are scheduled to present data from their Phase 1 dose-escalation trial of.

Datasets in focus at IASLC this weekend

This weekend is the  15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th.

Biocryst up on hope(hype) for HAE prophylaxis

In a previous post, Jason Chew provided some background and analysis on Biocryst (BCRX) BCX4161, an oral drug candidate for the treatment of hereditary angioedema (HAE). Biocryst’s stock is up.

MDVN – Confusion over PREVAIL data explained in a single graph

On Tuesday, the market was rather confused on what to make of the PREVAIL news. To be clear, this wasn’t entirely the market’s fault: Medivation released a poorly worded press.

Browsing 20 / articles